

The logo features the letters 'TTV' in a bold, red, italicized font, followed by 'BIOPHARM' in a white, italicized font with a registered trademark symbol. The entire logo is set against a black diamond-shaped background.

TTV[®] BIOPHARM

台灣東洋藥品

WELCOME TO JOIN US

December, 2020

Safe Harbor Statement

This presentation contains certain forward-looking statements.

These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1. pricing and product initiatives of competitors;
2. legislative and regulatory developments and economic conditions;
3. delay or inability in obtaining regulatory approvals or bringing products to market;
4. fluctuations in currency exchange rates and general financial market conditions;
5. uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;

6. increased government pricing pressures;
7. interruptions in production
8. loss of or inability to obtain adequate protection for intellectual property rights;
9. litigation;
10. loss of key executives or other employees; and
11. adverse publicity and news coverage.

TTY Biopharm cautions that this foregoing list of factors is not exhaustive. There may also be other risks that management is unable to predict at this time that may cause actual results to differ materially from those in forward-looking statements.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. TTY Biopharm undertakes no obligation to update publicly or revise any forward-looking statements. Any statements regarding earnings growth is not a profit forecast and should not be interpreted to mean that TTY Biopharm's earnings or earnings per share for this year or any subsequent period will necessarily match or exceed published earnings or earnings per share forecasts of TTY Biopharm Company Limited.

Agenda

Company Overview

Market Deployment


Pipeline Status

Financials & ESG Performance

Summary


Q&A

Structure




Revenue Breakdown

1-3Q/2020



■ Oncology ■ Infection ■ Healthcare ■ CDMO ■ other

1-3Q/2019



■ Oncology ■ Infection ■ Healthcare ■ CDMO ■ other

Major Products (1)

Oncology (TOT)

Intensive Care (TIT)

Health Care (THT)

UFUR
(友復膠囊)



Lipo-Dox
(力得微脂體
注射劑)



TS-1
(愛斯萬膠囊)



Lonsurf
(朗斯弗膜衣錠)



Thado
(賽得膠囊)



Gemis
(建仕注射液)



Zobonic
(抑骨凍晶靜脈
注射劑)



Ivic
(癌微可膜衣錠)



Asadin
(伸定注射劑)



Pexeda Inj.
(派癌休注射劑)



Epicin
(益彼欣注射液)



Painkyl
(平舒疼口頰溶片)



Oxalip
(歐力普注射劑)



Anazo
(安納柔膜衣錠)



Irino
(益立諾)



Tynen
(汰能注射劑)



Megest
(麥格斯口服
懸液劑)



Otril
(嘔速停靜脈
注射劑)



Folina
(芙琳亞錠)



Leavdo
(瑞伏駭膠囊)



TTY BIOPHARM
台灣東洋藥品

Major Products (2)

Oncology (TOT)

Intensive Care (TIT)

Health Care (THT)

Brosym C+S
(博益欣)



Colimycin
(克痢黴素注射劑)



Cubicin
(救必辛注射劑)



Algitab
(艾胃逆服)



BIO-CAL PLUS
(滋骨咀嚼錠)



Flucelvax
(輔流威適流感疫苗)



METACIN
(西腹黴素注射劑)



Lipo-AB
(立博黴)



Alginos
(胃逆舒)



Sulfin
(速復利錠)



Flusine
(弗路欣錠)



Maxtam
(抑西每靈注射劑)



Cepiro
(希比洛靜脈乾粉注射劑)



TTY BIOPHARM
台灣東洋藥品

Agenda

Company Overview

Market Deployment

Pipeline Status


Financials & ESG Performance

Summary

Q&A

Company Overview

- Branch Office/ Affiliate Company (分/子公司)
- In-Licensing Partner (合作夥伴)
- Out-licensing/ Agent/ CMO (經銷/代理/代工)






- Founded in 1960, restructured in 1996
- Traded in the Taiwan TPEX (2001, Code: 4105)
- Shares outstanding: 248.65 Million Shares (June, 2020)

- TTY Biopharm consolidated sales as of
1H/2020- NTD 1.995B (USD 68M)
2019- NTD 4.44B (USD 148M)
Headquarter: Taipei, Taiwan
Number of employees: 554

Overseas Market Revenue & Profit

Vietnam & Philippines turned into profit since 2018.



Transform of success from Southeast Asia to overseas markets as growth driver.

Agenda

Company Overview

Market Deployment

Pipeline Status

Financials & ESG Performance

Summary

Q&A

Product Pipeline

Product	type	indication	market value (USD Mn)	Original Pharma	Patent Expire	Expected to market
Pegylipo	liposome	Ovarian Cancer	600	JJ	2016	2023
Lipo AB	liposome	Fungal Infection	440	Gilead (liposome type)	2008	1H/2022
Leuprolide	microsphere	Prostate Cancer	1,240	TAP/ Abott & Takeda	2008	
Risperidone	microsphere	Mental Disorder	960	JJ (non microsphere)	2020	
Octreotide	microsphere	Acromegaly	1,630	Novartis	2017	2023
LGIA 10	microsphere	Diabetes	910			
Enx-201	liposome	MS Acute	1,700 (similar BBB diseases)			2025

Liposome & Microspheres as Technology Platform

TTY Development & License-in Products

TTY Development

Product	Type	Indication	Approval expected time
TTY_1	Generic	Acute Promyelocytic Leukemia, APL	USA 2021
TTY_2	Generic	Multiple Myeloma, MM	Taiwan 2022-2023 Thailand 2023-2024 Malaysia 2024-2025
TTY_3	New dosage form	Infection caused by Gram-negative bacteria	Taiwan 2022

License-in

Product	Indication	Partner	Expected to Market
TTY_X	Check Sedation General Anesthesia ICU Sedation	British Co.	2022
TTY_Y	Chicken Pox Prevention	Japan Co.	2022
TTY_Z	Multiple Myeloma	Taiwan Co.	2022
Trabectedin (Yondelis)	Soft Tissue Sarcoma	Spain Co.	2020.9

Overseas markets penetration & pipeline development as the Dual Growth Engine.

Agenda

Company Overview

Market Deployment


Pipeline Status

Financials & ESG Performance

Summary

Q&A

Financial Performance (Consolidated)



1~3Q/2020 Financials

NTD in Mn

Item	1~3Q/2020		1~3Q/2019		Variance	YoY
	Amount	%	Amount	%		
Net Sales	3,019	100%	3,355	100%	(336)	-10%
Gross Profit	1,930	64%	2,195	65%	(265)	-12%
Operating Expenses	(1,216)	40%	(1,211)	36%	(5)	-0.4%
Operating Profit	714	24%	985	29%	(271)	-28%
Non-Operating Income (Loss)	157	5%	134	4%	23	17%
Income before Tax	871	29%	1,119	33%	(248)	-22%
Net Income (Consolidated)	706	23%	891	26%	(185)	-21%
Net Income (TTY)	662	22%	869	25%	(207)	-24%
EPS (NT)	2.66		3.49		(0.83)	-24%
Gross Margin	63.9%		65.4%		-1.5%	
Operating Margin	23.7%		29.4%		-5.7%	
Net Margin	23.4%		26.5%		-3.2%	

Solid Balance Sheet and Stable Cash flow


Balance Sheet

NTD Mn	3Q 2020	4Q 2019	3Q 2019
Total Debt	2,500	1,933	2,100
Net Debt	(107)	(821)	(616)
Net Debt/Equity	-2%	-15%	-11%
Current Ratio	173%	164%	159%
Book value/share(NT\$)	20.8	22.4	22.3

Cash Flow

NTD Mn	1~3Q/2020	1~3Q/2019
from Operating	303	867
from Investing	115	(406)
from Financing	(459)	(553)
FX Impact	(41)	6
Net Cash Flow	(82)	(85)
Beginning Balance	2,422	2,372
Ending Balance	2,340	2,287

Dividend Payout



ESG Focus

Female Directors **2** were elected as directors to reflect gender diversity in the BoD.

4 Consecutive Years Ranked in the Top **5%** OTC companies by TWSE Corporate Governance Evaluation.

BoD Average **92.22%** attendance within a total **10** BoD meetings in 2019.

Independent Directors **3** independent directors make up **33.33%** of the overall Board of Directors.

2019 Top **10%** of TPEX-listed and OTC companies in non-financial nor electronic stocks with a market value of more than NT\$10 billion.

2019 Sustainable Development Committee & Corporate Governance Officer Established to implement the ethical management & social responsibility.

2020 Award of Best Companies to Work for in Asia 2020 Taiwan Edition.



Agenda

Company Overview

Market Deployment

Pipeline Status

Financials & ESG Performance

Summary

Q&A

Summary

Product Pipeline

- Lipo-AB and Pegylipo are targeted to market in 2022 and 2023 respectively.
- Implement the launch market plan of Octreotide in USA continuously.
- Continue to develop and build overseas markets.
- Expand the revenue scale through license-in and self-developed products.

Dividend Policy

- Maintain cash payout rate above 75%.

ESG Focus

- Keep delivering outstanding performance on Corporate Governance and strengthen Social and Environmental aspects.

2021 Business Outlook

- Revenue of domestic sales is expected to increase 5%-10% annually.
- Expand the scale of (public expense + self-pay) flu vaccine.
- Expected milestone income from global partners.
- Strengthen R&D capabilities and introduce new products through license-in actively.



Let's share and grow together
in this big family



東生華製藥
tsh biopharm



PharmaEngine

智擎生技製藥股份有限公司

